Less than four months after the European Medicines Agency recommended in July not to grant marketing authorisation for Leqembi™ (lecanemab) for the treatment of Alzheimer's disease, the EMA's Committee for Medicinal Products for Human Use (CHMP) has reassessed the available evidence to conclude that the benefits outweigh the risks.
Despite considerable advances in the discovery and development of new cancer drugs, there are significant disparities in both the availability and timeliness of these medicines around the world, with the poorest countries being left out, according to an analysis published in the journal BMJ Global Health. According to the study, few new cancer drugs were launched in low- and lower-middle-income countries, and the gap between rich and poor countries widened over the three decades between 1990 and 2022.
The U.S. FDA has approved a new drug—called Cobenfy—to treat the symptoms of schizophrenia. Unlike traditional treatments, which are based on blocking the effects of dopamine, its mechanism of action simulates the effects of another neurotransmitter, acetylcholine. It is the first drug to be approved with a different mechanism of action in over 70 years.
Rituximab and ocrelizumab are two antibodies with a similar mechanism of action that are used in the treatment of multiple sclerosis. Although the former had not shown benefits in primary progressive multiple sclerosis — which affects between 10% and 15% of patients — the latter is approved for this form of the disease. Now, a study conducted in France with more than 1,000 patients has found no benefits with either treatment, as they did not slow the progression of disability in these individuals. The results are published in the journal Neurology.
An international team of researchers has conducted a meta-analysis of 137 clinical trials involving nearly 90,000 people to assess the migraine efficacy of 17 available drugs. Their conclusions are that four drugs in the triptan group are more effective and cheaper than newer drugs such as gepants or lasmiditan, and that the efficacy of the latter is comparable to that of paracetamol and most anti-inflammatory drugs. The results are published in The BMJ.
A new study presented at the annual meeting of the European Association for the Study of Diabetes (EASD), being held in Madrid from September 9-13, and published simultaneously in the New England Journal of Medicine (NEJM), has revealed that liraglutide, an anti-obesity drug, is safe and effective in children aged 6-12 years.
The use of GLP-1 analog diabetes drugs-such as semaglutide, sold under the trade name Ozempic-is not linked to an increased risk of suicide, according to two studies published in JAMA Internal Medicine. The first, led by a U.S. team, analyzes data from more than 3,300 people who have participated in clinical trials. The second analyzes data from 124,517 users of these drugs in Sweden and Denmark, and compares them with an even larger group of people who used another type of diabetes medication.
In research using a WHO database of adverse drug reactions, the authors identified a signal of disproportionality of suicidal ideation with semaglutide, one of the drugs used to treat type 2 diabetes and obesity. The study, published in JAMA Network Open, did not find this signal for liraglutide, another drug indicated for these treatments.
The European Medicines Agency (EMA) has recommended not granting marketing authorization for Leqembi™ (lecanemab) for the treatment of Alzheimer's disease. The EMA's Committee for Medicinal Products for Human Use (CHMP) considers that its effect in delaying cognitive decline does not outweigh the risk of serious side effects associated with the drug, in particular swelling and possible bleeding in patients' brains. Leqembi™ was approved in 2023 in the United States.
A paper published today in the journal Science explores the potential of glucagon-like peptide-1 (GLP-1)-based drugs such as semaglutide to treat diseases beyond diabetes and obesity. For example, recent studies suggest that they could improve conditions ranging from depression to neurological disorders to cardiovascular and kidney disease.